NewsResearch
FDA Approval: Ipilimumab (Yervoy) for Melanoma
FDA approved Ipilimumab (Yervoy), an anti-CTLA-4 checkpoint inhibitor, for certain people with melanoma. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Historical context: this page explains an event dated 2011. It was published as an explainer on July 12, 2026 and is not breaking news.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Taking the brakes off the immune system
Ipilimumab, sold as Yervoy, carries an Initial U.S. Approval date of 2011. Its label describes it as a human cytotoxic T-lymphocyte antigen 4 blocking antibody, usually shortened to CTLA-4.
CTLA-4 is a brake. It sits on T cells, the immune system's attack cells, and its job is to stop them from running out of control. Tumors benefit from that brake staying on. Ipilimumab blocks CTLA-4, which releases the brake and lets T cells attack the cancer.
That is the whole idea behind checkpoint blockade, and this was the first drug of its kind to reach the clinic. The trade-off is built into the mechanism: an immune system with fewer brakes can attack healthy tissue too.
Our page on immunotherapy covers the wider class that grew out of this approach.
What the label covers
The current label spans several cancers.
For melanoma, it covers disease that cannot be removed by surgery, or that has spread. That use is for adults and children aged 12 and older, alone or with nivolumab. It also covers adjuvant treatment in adults with skin melanoma. There the cancer must involve regional lymph nodes by more than 1 millimeter, and must have been fully removed.
Beyond melanoma, the label includes advanced kidney cancer at intermediate or poor risk, with nivolumab, as first-line treatment. It also includes colorectal cancer that is microsatellite instability-high or mismatch repair deficient, again with nivolumab.
NCI's listing adds esophageal squamous cell carcinoma, hepatocellular carcinoma, malignant pleural mesothelioma, and non-small cell lung cancer, in defined combinations and settings.
The side effects are the mechanism
The label's leading warning is severe and fatal immune-mediated adverse reactions. The label states they can occur in any organ system or tissue, and at any time during treatment or after it has stopped.
It names the common patterns. Colitis is inflammation of the colon. Hepatitis is inflammation of the liver. Skin reactions are common. So are endocrinopathies, meaning damage to hormone glands such as the thyroid, pituitary, and adrenal. Pneumonitis is inflammation of the lungs. Nephritis harms the kidneys.
Monitoring is written into the label. Blood tests are done at the start and before each dose. They include liver enzymes, creatinine, a pituitary hormone level, and thyroid function.
The response rules are specific too. In general, the drug is held for severe, grade 3, reactions. It is stopped for good for life-threatening, grade 4, reactions. Infusion reactions are handled on their own. The team slows or pauses the infusion, and stops it for severe reactions.
For anyone on this treatment, new diarrhea, persistent belly pain, yellowing of the skin or eyes, a new cough or breathlessness, unusual fatigue, or a rash that spreads are all reasons to call the team the same day rather than wait.
When to get checked
NCI states that signs of melanoma include a change in the way a mole or pigmented area looks. Unusual moles, sun exposure, and health history all affect risk.
The ABCDE list is the standard prompt for a pigmented spot:
- A for asymmetry, where one half does not match the other.
- B for border, where the edge is ragged or blurred.
- C for color, where the shade is uneven.
- D for diameter, where the spot is usually larger than 6 millimeters.
- E for evolving, where the mole changes in size, shape, or color over time.
NCI lists other changes worth reporting too. A sore that does not heal. Pigment spreading past the edge of a spot. Redness or swelling around a mole. Itching, tenderness, or pain. Oozing or bleeding. A change in the surface, such as scaliness or a lump. Ulceration, where the top layer breaks down. And new moles growing near an existing one.
Melanoma can occur anywhere on the skin, including places that rarely see sun.
Biopsy, then the sentinel node
Melanoma starts in melanocytes, the cells that give skin its color. Diagnosis begins with a skin exam and then a biopsy. It can be hard to tell a benign mole from an early melanoma by eye. NCI notes that patients may want a second pathologist to review the sample.
If the sample is cancer, it may also be tested for gene changes that help plan treatment.
Staging depends on how likely the melanoma is to spread. For melanoma unlikely to spread or return, more tests may not be needed. For higher-risk melanoma, a sentinel lymph node biopsy is done. A radioactive substance or blue dye is injected near the tumor. The first node it reaches is removed and examined. If no cancer cells are found there, removing more nodes may not be needed. CT scanning looks for spread further afield.
Where this drug sits in treatment
Surgery remains the treatment for melanoma caught early, and it is often curative on its own.
Checkpoint inhibitors changed what happens after that. In the adjuvant setting, they are given after complete removal to lower the chance of return. In advanced disease, they are the backbone of treatment, alone or in combination. Our page on melanoma covers the stages and the options at each.
The numbers, and the slice this drug targets
These SEER figures describe the whole US population with melanoma of the skin. They are group statistics and describe no individual.
Five-year relative survival is 94.7 percent for cases from 2016 to 2022. By stage it is 100.0 percent while the melanoma is confined to the skin, 76.0 percent once it reaches nearby lymph nodes, and 34.0 percent once it has spread to distant organs. About 77 percent are found at that first stage, and 5 percent are distant at diagnosis. The American Cancer Society projects 112,000 new cases and 8,510 deaths for 2026, and NCI's registry data give a median age at diagnosis of 67.
The 5 percent found at a distance is a small slice of cases and a large share of the deaths. That is the group checkpoint blockade was built for.
What this does not mean
A 2011 approval date marks a beginning, not a finished story. The label has been revised repeatedly since, most recently in 2025, and the drug is now given mostly in combination rather than alone.
Immune-mediated reactions are not rare footnotes here. They are why this treatment needs close monitoring, and a team that spots the patterns early. Whether it fits one person depends on stage, on other health conditions, above all autoimmune disease, and on the goals of treatment.
Sources
- DailyMed, YERVOY (ipilimumab) label, Initial U.S. Approval 2011 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66
- NCI, Ipilimumab — https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab
- NCI PDQ, Melanoma Treatment (Patient Version) — https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq
- SEER Cancer Stat Facts, Melanoma of the Skin — https://seer.cancer.gov/statfacts/html/melan.html
- NCI, Skin Cancer (Including Melanoma) — https://www.cancer.gov/types/skin
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Melanoma. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.